Novo Nordisk A/S
GIP DERIVATIVES AND USES THEREOF

Last updated:

Abstract:

The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).

Status:
Application
Type:

Utility

Filling date:

3 May 2019

Issue date:

6 Jan 2022